Mobia Medical
Nasdaq-listed bioelectronic medicine company (NASDAQ MOBI) developing the Vivistim Paired Vagus Nerve Stimulation System, the only FDA-approved paired-VNS therapy for chronic stroke upper-limb recovery. Renamed from MicroTransponder in February 2026; IPO priced May 2026 at $15 with first-week trading -22%.
Overview
Mobia Medical is a Nasdaq-listed bioelectronic medicine company developing paired vagus nerve stimulation therapy for chronic stroke upper-limb recovery. The company was founded in 2007 as MicroTransponder, based in Austin, Texas, and rebranded to Mobia Medical in February 2026 four months ahead of its IPO filing. Mobia is the first major neurotech IPO of 2026.
The Vivistim System
The Vivistim Paired VNS System is an implanted pulse generator and lead that delivers timed electrical pulses to the vagus nerve during physical therapy sessions for chronic ischemic stroke patients with moderate-to-severe upper limb impairment. The stimulation is paired with specific arm movements during therapy, with the goal of using vagus nerve activation to amplify neuroplasticity and convert therapy gains into durable functional recovery. The device received FDA approval on 27 August 2021 and is currently the only FDA-approved paired-VNS therapy for chronic stroke recovery.
IPO and first-week trading
Mobia priced 10 million shares at $15 per share (the bottom of the $14-16 indicative range) on 7 May 2026, raising $150 million in gross proceeds. Trading opened on 8 May at $14 on the Nasdaq Global Select Market under the ticker MOBI and never crossed $15 in the first session. The stock drifted lower through the week to close 11 May at $11.75, a roughly 22% decline from the IPO price in three sessions. The offering closed on 11 May. BofA Securities, Piper Sandler, and Stifel led the underwriting syndicate.
Strategic context
The MOBI trade became the cleanest market signal for the broader pre-IPO bioelectronic-medicine cohort preparing 2026-27 listings (SetPoint Medical, BlueWind Medical, Salvia BioElectronics, Nervonik, Spark Biomedical). The 22% week-one drop suggested public-market investors are pricing these companies on near-term commercial execution and revenue trajectory rather than on platform-and-pipeline narratives. The print reset the implied exit math for the dozen-plus pre-IPO bioelectronic-medicine companies eyeing public capital, with the pattern of strategic M&A by top-three neuromodulation incumbents (Boston Scientific-Nalu, Medtronic-SPR Therapeutics) emerging as an alternative exit path.